New Hope and Current Challenges for Osteosarcoma Metastasis

Presentation Description / Summary: Despite significant progress in pediatric and veterinary oncology, OS remains one of the deadliest cancers. No significant outcome improvements have been made in either species in 30 years, with metastasis continuing to be the prevailing and deadly common denominator. The human OS development pathway includes a unique phase 2 trial design that examines novel therapeutics at the time of pulmonary recurrence. This investigational approach is currently absent in veterinary oncology, creating a translational imperative to remedy this, create a path to study the biology of metastasis in the dog, and build an integrated pathway to prioritize novel therapeutics through interrogation of metastatic tissue samples. Until now, metastasectomy has rarely been performed due to the perceived invasiveness of the procedure. Our preliminary data suggest thoracoscopic metastasectomy is associated with little morbidity and hints at an improved long-term outlook. Ethos Discovery seeks to evolve the existing perspective regarding OS metastasis in dogs and close the integration gap by leveraging our successfully recruiting MIMIC (Minimally Invasive Metastasectomy in Canines) trial to create alignment of the dog model with the OS patients of highest need, those with distant metastasis. In this presentation we will share our progress and review preliminary findings from the high-level evidence Ethos-MIMIC clinical trial which suggests that there is more hope for patients with stage III OS.

Learner Outcomes: Current treatment options for osteosarcoma metastasis, outcomes associated with thoracoscopic metastasectomy, use of liquid biopsy for osteosarcoma, and future targets for osteosarcoma metastasis.